openPR Logo
Press release

The Masonic Home of New Jersey, A Leading Senior Community, Goes Green

06-29-2011 09:49 AM CET | Health & Medicine

Press release from: Masonic Home of New Jersey

The Masonic Home of New Jersey, a leading senior care home providing assisted living, residential living, Alzheimer’s care, adult respite care, short term rehab, hospice care and more, is demonstrating environmental awareness with the installation of 5,600 ground-supported solar panels at its Burlington facility.

Upon completion, the panels will span more than seven acres of the Masonic Home property and generate about 1 MW of electricity. The solar power generated by the panels will account for approximately 11% of the facility’s energy.

Taking advantage of the latest technology at the Masonic Home is a top priority. “We strive to keep our facility at the forefront of technology to provide the best possible care professionally, personally and technically,” says David Dorworth of the Masonic Charity Foundation.

According to Dorworth, the panels feature a sleek design and strategically cover a vast area of the property. “The strategy behind the panels’ placement,” he explains, “stems from the focus of the Masonic Home to maintain an aesthetically-pleasing community for our residents and visitors. We believe very strongly in providing our residents with a beautiful, comfortable place to live. The placement of the newly installed panels helps to preserve the property’s natural beauty while helping to ease the Masonic Home’s environmental impact. We are very excited about how the solar panels will help to reduce energy consumption and costs, which will allow us to make greater investments in future improvement projects for the home.”

The Masonic Home of New Jersey is open to the public and provides assisted living, residential living, Alzheimer’s care, adult respite care, short term rehab, hospice care and long term care. Those who are interested in learning more about the facility and its recent environmental efforts can visit the Masonic Home of New Jersey’s newly designed website at http://www.njmasonic.org.

About the Masonic Home of New Jersey

Founded in 1898, the Masonic Home of New Jersey provides residential living, assisted living, long term skilled nursing, Alzheimer’s care, respite care, short term rehab and hospice care. The Masonic Home of New Jersey is situated on 450 acres of land in Burlington, New Jersey. The Masonic Home is conveniently located near a variety of cultural and entertainment venues in Philadelphia, Princeton and New York.

The Masonic Home of New Jersey is open to the public, and offers completely private, beautifully-decorated rooms to each and every resident.

For more information about the Masonic Home of New Jersey, call 609-239-3900 or visit http://www.njmasonic.org.

Masonic Home of New Jersey
902 Jacksonville Road
Burlington, NJ 08016

Linda Andress
609-239-3900

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release The Masonic Home of New Jersey, A Leading Senior Community, Goes Green here

News-ID: 181417 • Views: 2524

More Releases for Alzheimer’s

Global Alzheimer’s Drugs Market Analysis (2020-2025)
Global Info Research offers a latest published report on Alzheimer’s Drugs Analysis and Forecast 2020-2025 delivering key insights and providing a competitive advantage to clients through a detailed report. This report focuses on the key global Alzheimer’s Drugs Concentrate players, to define, describe and analyze the value, market share, market competition landscape, SWOT analysis and development plans in next few years. Click to view the full report TOC, figure and tables: https://www.globalinforesearch.com/reports/516177/alzheimer%25E2%2580%2599s-drugs Market
Global Alzheimer’s disease, Dementia and Ageing Awareness
Lexis brings in a new spin on conferences by presenting the latest scientific improvements in the fields of Neurology and Neuroscience. Zurich is all set for an amazing event as LEXIS proudly presents the “Global Alzheimers, Dementia and Ageing Awareness” slated on July 17-18, 2019 at Zurich, Switzerland. The theme of the conference is “Global Voice and Awareness on Alzheimers Disease and Dementia Care”. Avenue Roger VAndendriessche, 18 at 1150 BRUSSELS Avenue
Global Alzheimer’s disease (AD) Market to 2024
Market Overview, Key in-line Products, Market Share Distribution, Competitive Dynamics, Regulatory Outlook, Pipeline Development, Growth Catalysts & Challenges, Leading Market & R&D Trends, Partnership & Deals Analyses, Global Sales forecast of in-line and pipeline products, Fast Growing Private Companies, Management Perspectives, Commentaries, Market Outlook & Summary Conclusions Global Alzheimer’s disease (AD) market was valued at $3.1bn in 2015 and is forecast to grow at a modest 5.3% CAGR between 2015
Europe Alzheimer’s Drug Pipeline Analysis
The incidence of Alzheimer’s disease has been on a rise in Europe in recent years and it most likely to continue rising in the near future. It has been observed that close to 50% of dependency of aged people in Europe is attributed for by Alzheimer’s disease. The rapid growth in the prevalence of Alzheimer's disease over the next few decades in Europe is expected to result in immense pressure
Alzheimer’s Disease Therapeutics Market Forecast – (2016-2020)
Alzheimer’s Disease Therapeutics in Major Developed Markets to 2021 - Aging Population and Improved Disease Understanding Increase Demand for Disease Modifying Agents Summary of the report: Alzheimer's Disease (AD) is an irreversible, progressive neurodegenerative disease, characterized by cognitive impairment, memory loss and functional decline. Symptoms typically begin to first appear in patients in their mid-sixties, with symptoms appearing in varying stages. The pathological features of AD comprise histopathological changes within the brain.
Otava Alzheimer’s Disease Targeted Libraries
Alzheimer’s disease (AD) is a devastating and always fatal neurodegenerative disorder characterized by progressive impairment of cognitive function and emotional disturbances. Currently, more than 25 million people worldwide live with AD. But there is no cure for AD and no treatment to reverse its progression, there are medicines available that can help treat symptoms in some people with this disease. Intensive scientific research around the world brings us closer to